Kiromic Biopharma Inc (KRBP) - Total Liabilities
Based on the latest financial reports, Kiromic Biopharma Inc (KRBP) has total liabilities worth $21.13 Million USD as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Kiromic Biopharma Inc (KRBP) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Kiromic Biopharma Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Kiromic Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Kiromic Biopharma Inc balance sheet assets.
Kiromic Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Kiromic Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UMT United Mobility Technology AG
XETRA:UMDK
|
Germany | €4.28 Million |
|
Rua Life Sciences PLC
LSE:RUA
|
UK | GBX1.89 Million |
|
Gangotri Textiles Limited
NSE:GANGOTRI
|
India | Rs2.52 Billion |
|
TRELLUS HEALTH LS -0006
F:85Q
|
Germany | €513.00K |
|
ImmuPharma PLC
LSE:IMM
|
UK | GBX1.24 Million |
|
Inspiration Healthcare Group PLC
LSE:IHC
|
UK | GBX20.34 Million |
|
NAHL Group PLC
LSE:NAH
|
UK | GBX26.47 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Kiromic Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See KRBP equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kiromic Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kiromic Biopharma Inc (2018–2024)
The table below shows the annual total liabilities of Kiromic Biopharma Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $21.13 Million | -0.74% |
| 2023-12-31 | $21.29 Million | +20.00% |
| 2022-12-31 | $17.74 Million | +420.33% |
| 2021-12-31 | $3.41 Million | +132.34% |
| 2020-12-31 | $1.47 Million | +117.84% |
| 2019-12-31 | $673.70K | +10.32% |
| 2018-12-31 | $610.70K | -- |
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more